Catheter PrecisionVTAK
VTAK
About: Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System) which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.
Employees: 14
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
3.61% less ownership
Funds ownership: 9.36% [Q2] → 5.75% (-3.61%) [Q3]
21% less funds holding
Funds holding: 14 [Q2] → 11 (-3) [Q3]
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
88% less capital invested
Capital invested by funds: $415K [Q2] → $50.8K (-$364K) [Q3]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 6
Research analyst outlook
We haven’t received any recent analyst ratings for VTAK.
Financial journalist opinion
Based on 4 articles about VTAK published over the past 30 days
Neutral
Accesswire
4 days ago
Catheter Precision to Attend the 30th International Atrial Fibrillation Symposium
FORT MILL, SOUTH CAROLINA / ACCESS Newswire / January 16, 2025 / Catheter Precision, Inc. (NYSE American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 30th International Atrial Fibrillation Symposium in from January 16 - 18, 2025 in Boston, Massachusetts. The AF Symposium was initiated in 1995 in response to the growing epidemic of atrial fibrillation.
Neutral
Accesswire
5 days ago
Catheter Precision, Inc. Announces Definitive Agreement to Acquire PeriKard, LLC
FORT MILL, SC / ACCESSWIRE / January 15, 2025 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has entered into a definitive agreement to acquire PeriKard, LLC., in a transaction involving the issuance of restricted VTAK common stock for 100% of the LLC interests in PeriKard.
Neutral
Accesswire
1 week ago
Catheter Precision, Inc. Announces Initial LockeT Purchase From the University of Tennessee Medical Center
FORT MILL, SC / ACCESSWIRE / January 13, 2025 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced it has received its first purchase order for LockeT from the southeast region. As previously announced, the company has recently expanded its US sales and clinical team in preparation for the national product launch of LockeT.
Neutral
Accesswire
1 week ago
Catheter Precision, Inc. Announces New Chief Financial Officer
FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.
Neutral
Accesswire
2 months ago
Catheter Precision, Inc. Announces Initial LockeT Purchase From Montefiore Medical Center
FORT MILL, SC / ACCESSWIRE / November 14, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced it has received its first purchase order for LockeT from the New York City area. As previously announced, the company has recently expanded their US sales and clinical team in preparation for the national product launch of LockeT which includes the NYC region.
Neutral
Accesswire
2 months ago
Catheter Precision, Inc. Announces Third Quarter Update and Financial Results
FORT MILL, SC / ACCESSWIRE / November 13, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending September 30, 2024. Highlights of the third quarter include: Commercial Endeavors Marie-Claude Jaques, our new Chief Commercial Officer, has now completed her first full quarter of engagement with the company, along with many of the new sales and clinical persons brought on board midway through the second quarter.
Neutral
Accesswire
2 months ago
Catheter Precision, Inc. Announces New Clinical Data Presented at SCRN
FORT MILL, SC / ACCESSWIRE / November 4, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced that new clinical data from the VIVO EU Registry was presented last week at the Society of Cardiac Robotic Navigation (SCRN) meeting in Lisbon, Portugal. As previously announced, there were three presentations about VIVO during the SCRN meeting which took place October 28-29.
Neutral
Accesswire
2 months ago
Catheter Precision, Inc. Announces Exercise of Warrants for $4.9 Million of Gross Proceeds
FORT MILL, SC / ACCESSWIRE / October 25, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding Series E, Series F, Series G, Series H and Series I warrants (collectively, the "Existing Warrants") to purchase up to an aggregate of 5,347,981 shares of the Company's stock at a reduced exercise price of $0.70 for total gross proceeds of approximately $3.7 million. An additional $1,185,000 of gross proceeds were received through the exercise of warrants over the last week in accordance with their original terms.
Neutral
Accesswire
2 months ago
Catheter Precision to Attend Society for Cardiac Robotic Navigation With New Clinical Data Presented on October 28 – 29
FORT MILL, SC / ACCESSWIRE / October 23, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products announced that there will be two presentations showcasing the VIVO technology at the International Society for Cardiac Robotic Navigation Meeting (SCRN) October 28-29 in Lisbon, Portugal. The 2024 program highlights VIVO in the presentations.
Neutral
Accesswire
3 months ago
Catheter Precision Announces Clinical Publication of Non-Invasive Stereotactic Radioablation Using VIVO
FORT MILL, SC / ACCESSWIRE / October 21, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced a new publication in the October 2024 issue of HeartRhythm Case Reports. This recent publication focuses on a patient procedure in which a novel, non-invasive ablation technique known as stereotactic radioablation ("STAR") was used.
Charts implemented using Lightweight Charts™